Literature DB >> 14980548

Beyond the red cell: pegylation of other blood cells and tissues.

Mark D Scott1, Audrey M Chen.   

Abstract

Immunological recognition of allogeneic tissue is of critical concern in transfusion and transplantation medicine. While the major emphasis of our work on the immunocamouflage of cells has been focused on the erythrocyte, we have extended this research beyond the red blood cell (RBC) to other tissues. Our studies from blood transfusion (i.e., a specialized form of cellular transplantation) suggest that covalent modification of cells and tissues with methoxypoly(ethylene glycol) mPEG can significantly diminish immunologic recognition of other allogeneic tissues and, furthermore, may enhance the induction of tolerance. The mechanisms underlying the mPEG-mediated immunocamouflage of alloantigens is the global camouflaging of antigenic sites, membrane surface charge and the attenuation of receptor-ligand and cell-cell interactions. As a consequence of the immunocamouflage imparted by the grafted mPEG, weak costimulation of alloreactive T cells is observed which subsequently induces apoptosis of these reactive cells. As a result of this clonal deletion, a pro-tolerance state is induced. The potency of immunocamouflage is readily observed in in vivo murine models of transfusion-associated graft versus host disease. Furthermore, initial studies on the in vivo transplantation of pegylated rat and murine pancreatic islets have demonstrated that mPEG-derivatization does not impair the finely tuned signaling necessary for glucose homeostasis. Finally, in contrast to the pharmacological inhibition of the immune response by agents such as cyclosporine, mPEG-mediated immunocamouflage directly attenuates the inherent antigenicity and immunogenicity of the donor tissue itself while leaving the recipient a fully competent immune system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14980548     DOI: 10.1016/j.tracli.2003.12.005

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  7 in total

Review 1.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

Review 2.  Harnessing Biology to Deliver Therapeutic and Imaging Entities via Cell-Based Methods.

Authors:  Bishnu P Joshi; Joseph Hardie; Michelle E Farkas
Journal:  Chemistry       Date:  2018-05-14       Impact factor: 5.236

3.  Pancreas preservation for pancreas and islet transplantation.

Authors:  Yasuhiro Iwanaga; David Er Sutherland; James V Harmon; Klearchos K Papas
Journal:  Curr Opin Organ Transplant       Date:  2008-08       Impact factor: 2.640

Review 4.  Nanotechnology Approaches to Modulate Immune Responses to Cell-based Therapies for Type 1 Diabetes.

Authors:  Sydney C Wiggins; Nicholas J Abuid; Kerim M Gattás-Asfura; Saumadritaa Kar; Cherie L Stabler
Journal:  J Diabetes Sci Technol       Date:  2019-09-06

5.  A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.

Authors:  Zhifeng Huang; Huiyan Wang; Meifei Lu; Chuanchuan Sun; Xiaoping Wu; Yi Tan; Chaohui Ye; Guanghui Zhu; Xiaojie Wang; Lu Cai; Xiaokun Li
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

Review 6.  Cell microencapsulation with synthetic polymers.

Authors:  Ronke M Olabisi
Journal:  J Biomed Mater Res A       Date:  2014-08-18       Impact factor: 4.396

7.  Optimization of monomethoxy poly(ethylene glycol) grafting on Langerhans islets capsule using response surface method.

Authors:  Hamideh Aghajani-Lazarjani; Ebrahim Vasheghani-Farahani; Sameereh Hashemi-Najafabadi; Seyed Abbas Shojaosadati; Saleh Zahediasl; Taki Tiraihi; Fatemeh Atyabi
Journal:  Prog Biomater       Date:  2013-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.